tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TCR2 Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Robert Burns downgraded TCR2 Therapeutics (TCRR) to Neutral from Buy without a price target after the company entered into a definitive merger agreement under which Adaptimmune (ADAP). The all-stock deal values TCR2 at a "hefty discount" to its most recently reported cash position, the analyst tells investors in a research note.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on TCRR:

Disclaimer & DisclosureReport an Issue

1